Brief: Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics

09/07/2024 14:21

July 9 (Reuters) - Zevra Therapeutics Inc  ZVRA.O :
    * ZEVRA ANNOUNCES FDA ADVISORY COMMITTEE MEETING TO REVIEW
ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C
    * ZEVRA THERAPEUTICS: FDA TO CONVENE MEETING WITH GENETIC
METABOLIC DISEASES ADVISORY COMMITTEE ON AUGUST 2, TO REVIEW NDA
FOR ARIMOCLOMOL

Source text for Eikon:  ID:nGNX88k1yH 
Further company coverage:  ZVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))